These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8121042)

  • 21. Amantadine hydrochloride in treatment of Parkinsonism.
    Nagaswami S; Nagaswami R
    Dis Nerv Syst; 1973; 34(5):253-8. PubMed ID: 4782280
    [No Abstract]   [Full Text] [Related]  

  • 22. [Parkinsonism due to the medication].
    Louter M; Tromp SC
    Ned Tijdschr Geneeskd; 2009; 153():A336. PubMed ID: 19900308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A 62-year-old man with familial parkinsonism with the onset at 24 years of the age].
    Takubo H; Kondo T; Mori H; Miyake T; Suda K; Yokochi M; Imai H; Mizuno Y
    No To Shinkei; 1996 Jun; 48(6):587-97. PubMed ID: 8703564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Portable device for quantifying parkinsonian wrist rigidity.
    Caligiuri MP
    Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
    Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
    Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions.
    van Zagten M; Lodder J; Kessels F
    Mov Disord; 1998 Jan; 13(1):89-95. PubMed ID: 9452332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism.
    Brar S; Henderson D; Schenck J; Zimmerman EA
    Arch Neurol; 2009 Mar; 66(3):371-4. PubMed ID: 19273756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Age characteristics of the development of a reserpine model of parkinsonism in rats].
    Rushkevich IuE
    Biull Eksp Biol Med; 1987 Dec; 104(12):654-7. PubMed ID: 3689952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antioxidant and cholinergic neuroprotective mechanisms in experimental parkinsonism.
    Dajas F; Costa G; Abin-Carriquiry JA; Echeverry C; Martínez-Borges A; Dajas-Bailador F
    Funct Neurol; 2002; 17(1):37-44. PubMed ID: 12086112
    [No Abstract]   [Full Text] [Related]  

  • 30. Vascular parkinsonism--an important cause of parkinsonism in older people.
    Thanvi B; Lo N; Robinson T
    Age Ageing; 2005 Mar; 34(2):114-9. PubMed ID: 15713855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging findings of shoulders in Parkinson's disease.
    Yucel A; Kusbeci OY
    Mov Disord; 2010 Nov; 25(15):2524-30. PubMed ID: 20818664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study.
    Gouider-Khouja N; Vidailhet M; Bonnet AM; Pichon J; Agid Y
    Mov Disord; 1995 May; 10(3):288-94. PubMed ID: 7651445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Juvenile parkinsonism--some clinical, pharmacological, and neuropathological aspects.
    Yokochi M; Narabayashi H; Iizuka R; Nagatsu T
    Adv Neurol; 1984; 40():407-13. PubMed ID: 6141711
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cerebrovascular parkinsonism--clinicopathologic study].
    Yamanouchi H; Nagura H
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1457-8. PubMed ID: 8752429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinsonism as an initial manifestation of brain tumor.
    Chang DC; Lin JJ; Lin JC
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Aug; 63(8):658-62. PubMed ID: 10969454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinico-pathomorphologic correlations in parkinsonism].
    Starikov AS; Obraztsova RG; Kleĭn AV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(12):28-32. PubMed ID: 6762023
    [No Abstract]   [Full Text] [Related]  

  • 39. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY; Li YX; Zee CS
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute and persistent parkinsonism after use of diquat.
    Sechi GP; Agnetti V; Piredda M; Canu M; Deserra F; Omar HA; Rosati G
    Neurology; 1992 Jan; 42(1):261-3. PubMed ID: 1734316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.